Alberto Raggi1, Licia Grazzi2, Erika Guastafierro3, Alessia Marcassoli3, Marco Passavanti3, Danilo Antonio Montisano2, Domenico D'Amico2. 1. UO Neurologia Salute Pubblica E Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy. alberto.raggi@istituto-besta.it. 2. UO Neuroalgologia - Centro Cefalee, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy. 3. UO Neurologia Salute Pubblica E Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milan, Italy.
Abstract
BACKGROUND: Chronic migraine (CM) is one of the most disabling neurological diseases, often associated to medication overuse headache (MOH). These patients make high use of pharmacological and non-pharmacological treatments, and experience high work-related indirect costs. The aim of this study was to address and compare the main driver of cost associated to CM-MOH and EM, and to evaluate the effect of improvement in migraine profile on disease cost. METHODS: We selected patients with baseline CM-MOH who reverted to an episodic pattern by 3 months after structured withdrawal. Paired sample t-test was used to explore the variation in headache frequency and its costs. Regression models were run to address the impact of single cost categories on total migraine cost. RESULTS: A total of 261 patients were included. Significant reductions in headache frequency and its costs were observed, with the exception of medical prophylaxis cost. The cost of migraine from chronic to episodic pattern is reduced by 533€ per month and 80% of this reduction is accountable to reduced indirect costs, i.e., loss of productive time. CONCLUSIONS: The results of our study open to future considerations on future approaches to the treatment of CM-MOH in which new migraine-specific treatments, i.e., monoclonal antibodies, should be combined with other pharmacological and non-pharmacological ones.
BACKGROUND: Chronic migraine (CM) is one of the most disabling neurological diseases, often associated to medication overuse headache (MOH). These patients make high use of pharmacological and non-pharmacological treatments, and experience high work-related indirect costs. The aim of this study was to address and compare the main driver of cost associated to CM-MOH and EM, and to evaluate the effect of improvement in migraine profile on disease cost. METHODS: We selected patients with baseline CM-MOH who reverted to an episodic pattern by 3 months after structured withdrawal. Paired sample t-test was used to explore the variation in headache frequency and its costs. Regression models were run to address the impact of single cost categories on total migraine cost. RESULTS: A total of 261 patients were included. Significant reductions in headache frequency and its costs were observed, with the exception of medical prophylaxis cost. The cost of migraine from chronic to episodic pattern is reduced by 533€ per month and 80% of this reduction is accountable to reduced indirect costs, i.e., loss of productive time. CONCLUSIONS: The results of our study open to future considerations on future approaches to the treatment of CM-MOH in which new migraine-specific treatments, i.e., monoclonal antibodies, should be combined with other pharmacological and non-pharmacological ones.
Authors: M Linde; A Gustavsson; L J Stovner; T J Steiner; J Barré; Z Katsarava; J M Lainez; C Lampl; M Lantéri-Minet; D Rastenyte; E Ruiz de la Torre; C Tassorelli; C Andrée Journal: Eur J Neurol Date: 2011-12-05 Impact factor: 6.089
Authors: Elio Clemente Agostoni; Piero Barbanti; Paolo Calabresi; Bruno Colombo; Pietro Cortelli; Fabio Frediani; Pietrangelo Geppetti; Licia Grazzi; Massimo Leone; Paolo Martelletti; Luigi Alberto Pini; Maria Pia Prudenzano; Paola Sarchielli; Gioacchino Tedeschi; Antonio Russo Journal: J Headache Pain Date: 2019-08-30 Impact factor: 7.277
Authors: Licia Grazzi; Claudia Toppo; Domenico D'Amico; Matilde Leonardi; Paolo Martelletti; Alberto Raggi; Erika Guastafierro Journal: Int J Environ Res Public Health Date: 2021-02-05 Impact factor: 3.390
Authors: Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin Journal: J Headache Pain Date: 2012-05 Impact factor: 7.277